Antegenes appoints its first advisory board member Akshay Mody

8 Oktober 2020

Antegenes is proud to appoint its first advisory board member Akshay Mody, who brings his expert advice and guidance as a medical leader, in order to help us successfully develop and launch our innovative products in healthcare.

Akshay Mody has spent over 20 years in the healthcare industry. His most recent experience is in overseeing the rapid growth of the medical organisation Viiv Healthcare as Chief of Staff, which successfully concluded 7 Phase 3 trials (resulting in 4 NDAs) and established a portfolio of Discovery and Early Development products in just 5 years. This has given him a unique understanding of managing successful short- and long-term objectives in parallel with expansion. This experience, linked to his earlier roles leading multifunctional teams in global and European launches for assets at GlaxoSmithKline, launching breakthrough specialist drugs in multiple therapy areas as a Regional and Country General Manager (at Roche, Novartis and Ciba-Geigy) will allow our executive management team of Antegenes to have the support we need at this important stage of growth.

With the establishment of the advisory board, our intention is to identify a group of people who have vast experience in their respective fields. The board’s mission is to provide our executive team objective judgement that is critical to us in establishing our identity, footprint and ultimately fulfilling our mission to empower individuals, medical professionals and public healthcare in using genetics for personal and public health activities.

Our advisory board members will provide us unbiased advice in areas such as strategy, performance, sustainability, resources, transformation, diversity, standards of conduct and evaluation of performance. We believe this will help guide, improve and evolve our corporate credibility and governance standards and also manage risks while focusing on bringing our solutions to patients and healthcare providers.